| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_eb0168d41795f5f49377176ac2c3035e |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-135
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-137 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-137
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-135
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K45-06 |
| filingDate |
2001-06-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate |
2002-07-16-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ac818d65b02802ba301dd751930e7f17 |
| publicationDate |
2002-07-16-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-6420433-B2 |
| titleOfInvention |
S(+) desmethylselegiline and drug withdrawal |
| abstract |
The present invention provides novel compositions and methods for using the S-(+) enantiomer of desmethylselegiline (N-methyl-N-(prop-2-ynyl)-2-aminophenylpropane), for the treatment of selegiline-responsive diseases and conditions. Diseases and conditions responsive to selegiline include those produced by neuronal degeneration or neuronal trauma and those due to immune system dysfunction. Effective dosages are a daily dose of at least about 0.0015 mg/kg of body weight. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-8182836-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-8425933-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-8692030-B1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-8703186-B2 |
| priorityDate |
1995-01-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |